Trading Analysis Report: CC
- Analysis date: 2026-05-31
- Processed decision: Hold
- Price Target: 25
I. Analyst Team Reports
Market Analyst
Market Report
Chemours (CC) closed at $22.16 on May 29, 2026, below its $23.07 50-day average but above its $16.95 200-day average. The stock traded between $9.13 and $28.67 over the past year, and yfinance history showed a one-year return of about 118.8%.
The market setup is balanced. yfinance showed a market capitalization of about $3.33 billion, enterprise value of about $7.16 billion, total cash of about $563 million, total debt of about $4.39 billion, and a dividend yield of about 1.58%. Analyst data showed 9 opinions, a Buy recommendation key, mean target $26.33, and median target $26.00.
Q1 2026 results were mixed. Net sales were $1.381 billion, up 1% year over year. Adjusted EBITDA was $169 million, up 2%, but Chemours still reported a $29 million net loss, or $0.19 per diluted share.
Segment quality was uneven. Thermal & Specialized Solutions was strong, with net sales up 22% and adjusted EBITDA up 35% to $190 million. Titanium Technologies adjusted EBITDA fell 64% to $18 million, and Advanced Performance Materials adjusted EBITDA fell 84% to $5 million.
Market read: CC has improving refrigerants momentum and Q2 cash-flow upside, but leverage and environmental/PFAS liabilities keep risk elevated. Assign Hold with a $25 target.
Sentiment Analyst
Sentiment Report
Sentiment toward CC is improving but still cautious. Bulls focus on TSS strength, Opteon and Freon demand, Kuan Yin asset-sale proceeds, debt repayment, Q2 adjusted EBITDA guidance, and the dividend.
The Q1 release gave bulls real support. TSS revenue increased 22% to $568 million, TSS adjusted EBITDA increased 35% to $190 million, and TSS adjusted EBITDA margin reached 33%. Management also guided Q2 adjusted EBITDA to $220 million to $250 million and free cash flow of at least $100 million.
The negative sentiment case is persistent. Chemours had a Q1 net loss of $29 million, total debt around $4.2 billion, net debt of $3.6 billion, and net leverage of about 4.9x. PFAS and environmental matters remain a major investor overhang.
Titanium Technologies and Advanced Performance Materials were weak. TT adjusted EBITDA fell 64%, and APM adjusted EBITDA fell 84%, with the Washington Works outage contributing about $25 million of related impact.
Sentiment read: CC is recovering, but the market needs sustained debt reduction and fewer legal/environmental surprises before a stronger rating is warranted.
News Analyst
News Report
The key news item is Chemours' May 5, 2026 Q1 2026 release and Form 10-Q for the quarter ended March 31, 2026.
Headline sales were stable. Net sales were $1.381 billion, up 1% year over year, driven by 2% price and 3% currency, offset by a 4% volume decline. Adjusted EBITDA was $169 million, up 2%.
The income statement remained weak on a GAAP basis. Net loss attributable to Chemours was $29 million, or $0.19 per diluted share, compared with a $5 million loss, or $0.03 per diluted share, in Q1 2025.
Asset-sale and debt news were constructive. Chemours completed the sale of nine of ten Kuan Yin land parcels in April 2026 and received approximately $287 million of net cash proceeds. It used proceeds and cash to repay EUR 140 million of B-3 Euro term loans due August 2028.
News read: Q2 guidance and debt repayment are positives, but the operating base is uneven and the legal/environmental overhang remains important.
Fundamentals Analyst
Fundamentals Report
Chemours is a leveraged specialty-chemicals company with leading positions in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials.
Q1 showed that TSS is carrying the portfolio. TSS net sales were $568 million, up 22%, and adjusted EBITDA was $190 million, up 35%. Opteon Refrigerants sales rose 12%, and Freon Refrigerants sales rose 67%.
The rest of the portfolio was weaker. Titanium Technologies net sales were $559 million, down 6%, and adjusted EBITDA was $18 million, down 64%. Advanced Performance Materials net sales were $243 million, down 17%, and adjusted EBITDA was $5 million, down 84%.
Leverage is the main balance-sheet issue. Consolidated gross debt was $4.2 billion, net debt was $3.6 billion, and net leverage was about 4.9x on trailing twelve-month adjusted EBITDA. Total liquidity was $1.5 billion.
Environmental liabilities remain material. The 10-Q showed current environmental remediation liabilities of $97 million and long-term environmental remediation liabilities of $520 million. Fundamental read: the business can generate EBITDA, but leverage and liabilities cap the multiple.
II. Research Team Decision
Bull Researcher
Bull Research
The bull case is that CC is entering a stronger seasonal period with a high-quality TSS engine. Management guided Q2 net sales up 15% to 20% sequentially, adjusted EBITDA of $220 million to $250 million, and free cash flow of at least $100 million.
TSS is a clear strength. Q1 TSS adjusted EBITDA was $190 million, adjusted EBITDA margin was 33%, and Opteon and Freon demand remained strong.
Balance-sheet actions are helping. The Kuan Yin sale generated about $287 million of net cash proceeds, and Chemours paid down EUR 140 million of term loans.
Analyst targets support some upside. yfinance showed a $26.33 mean target and $26.00 median target versus the $22.16 latest close.
Bull conclusion: CC can move higher if Q2 guidance is delivered and proceeds are used for further debt reduction.
Bear Researcher
Bear Research
The bear case is leverage and liabilities. Gross debt was $4.2 billion, net debt was $3.6 billion, and net leverage was about 4.9x. That is high for a cyclical chemical producer.
Environmental and PFAS risk remains material. The 10-Q showed $97 million of current environmental remediation liabilities and $520 million of long-term environmental remediation liabilities, plus restricted cash tied to MOU escrow payments with DuPont, Corteva, and EID.
The segment mix is uneven. TT adjusted EBITDA fell 64%, and APM adjusted EBITDA fell 84%. The Washington Works outage and weaker cyclicals show how quickly earnings can deteriorate outside TSS.
GAAP earnings remain negative. Q1 net loss attributable to Chemours was $29 million, and yfinance showed trailing EPS of negative $2.73.
Bear conclusion: CC deserves a discount until leverage, environmental uncertainty, and non-TSS weakness improve.
Research Manager
Research Manager Synthesis
The bull case is credible: TSS is strong, Q2 guidance is better, Kuan Yin proceeds allow debt repayment, and analyst targets suggest moderate upside.
The bear case is equally important: CC remains leveraged, GAAP earnings are negative, TT and APM are weak, and PFAS/environmental liabilities continue to weigh on the equity.
The correct stance is Hold. The stock is not expensive versus analyst targets, but the quality of earnings and balance sheet are not strong enough for a Buy.
Synthesis: assign Hold with a $25 target, below the yfinance mean/median targets but above the latest price.
III. Trading Team Plan
Trader
Trader View
CC is above its 200-day average but below its 50-day average, which suggests the recovery trend is intact but near-term momentum has cooled.
The upside trading reference is the analyst target zone around $26 and the 52-week high near $28.67. The downside reference is the 200-day average near $16.95 if Q2 guidance or debt reduction disappoints.
The next catalysts are Q2 delivery, free cash flow conversion, debt paydown, TiO2 pricing, TSS seasonality, and environmental/PFAS developments.
Trading plan: Hold. Add only if Q2 free cash flow and debt reduction confirm the improvement.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk View
Aggressive investors can hold CC because TSS has strong momentum and Q2 free cash flow guidance is positive.
If adjusted EBITDA reaches the $220 million to $250 million Q2 range and cash flow exceeds $100 million, leverage concerns could ease.
The risk is that PFAS headlines, TiO2 weakness, or another operational outage can overwhelm the TSS recovery.
Aggressive conclusion: upside exists, but leverage requires disciplined sizing.
Conservative Analyst
Conservative Risk View
Conservative investors should be cautious. CC has substantial debt, environmental remediation liabilities, and exposure to cyclical chemical demand.
The dividend is modest, and the stock's recovery already reflects some improvement. A single strong segment does not remove portfolio and legal risk.
The conservative trigger for a better rating would be sustained free cash flow, lower net leverage, and clearer PFAS/environmental liability visibility.
Conservative conclusion: Hold, not Buy.
Neutral Analyst
Neutral Risk View
The neutral view is that CC's risk-reward is fair. TSS strength and Q2 guidance support the equity, while debt and PFAS liabilities cap the multiple.
A $25 target is appropriate because it gives credit for adjusted EBITDA improvement and debt repayment without ignoring the 4.9x net leverage ratio.
Key checkpoints are Q2 adjusted EBITDA, free cash flow, net debt, TiO2 demand, APM outage recovery, and environmental remediation updates.
Neutral conclusion: Hold is the cleanest rating.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Rating: Hold Price Target: 25
Horizon: 6-12 months Current Price Reference: $22.16 close on 2026-05-29
Chemours has a credible recovery path, but it is still a leveraged and legally complex chemical equity. Q1 2026 net sales were $1.381 billion, adjusted EBITDA was $169 million, and TSS delivered strong results with $568 million of sales and $190 million of adjusted EBITDA.
The Q2 outlook is encouraging. Management expects sequential consolidated sales growth of 15% to 20%, adjusted EBITDA of $220 million to $250 million, and free cash flow of at least $100 million. Kuan Yin proceeds of about $287 million and repayment of EUR 140 million of term loans also support the deleveraging story.
The risks are still material. Chemours reported a Q1 net loss of $29 million, net debt of $3.6 billion, net leverage of about 4.9x, current environmental remediation liabilities of $97 million, and long-term environmental remediation liabilities of $520 million. TT and APM were also weak in Q1.
The $25 target sits below yfinance's mean and median targets near $26 because the equity should retain a discount for leverage and environmental/PFAS uncertainty. The rating would become more constructive if Chemours delivers Q2 free cash flow, reduces debt further, and stabilizes TT and APM.